Sanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage Trial
By Adria Calatayud
Sanofi said a late-stage clinical trial for its Sarclisa drug in combination with other drugs met its primary goal of progression-free survival in patients with newly diagnosed multiple myeloma.
The French pharmaceutical company said Thursday the results came from a planned interim analysis for efficacy in a phase 3 trial that studies the investigational use of Sarclisa in combination with standard-of-care bortezomib, lenalidomide and dexamethasone against the standard of care alone.
The safety and tolerability of Sarclisa in the trial was consistent with its established safety profile, Sanofi said.
The company said the study results will form the basis of a future regulatory submission.
"This is the second phase 3 trial investigating Sarclisa in newly diagnosed patients to show superiority versus standard of care, reinforcing our belief in Sarclisa as a best-in-class medicine," said Dietmar Berger, Sanofi's global head of development.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
December 07, 2023 02:19 ET (07:19 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy